Yahoo Web Search

Search results

1. • 

     Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

     Investor's Business Daily· 1 day ago

     Regeneron Stock: Better Than Feared Abrahams kept his outperform rating and 1,189 price target on ...

2. • 

     Regeneron Pharma earnings missed by $0.64, revenue fell short of estimates By Investing.com

     Investing.com· 2 days ago

     Regeneron Pharma earnings missed by $0.64, revenue fell short of estimates

3. • 

     Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be...

     Simply Wall St. via Yahoo Finance· 2 days ago

     It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent...

4. • 

     Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight

     GuruFocus.com via Yahoo Finance· 1 day ago

     Regeneron must also remain vigilant against competitive threats and regulatory changes that could...

5. • Why Investors Are Eyeing Regeneron Pharmaceuticals Inc (REGN): T

     Guru Focus· 15 hours ago

     Regeneron Pharmaceuticals Inc (REGN) has recently captured the attention of investors and financial analysts alike, thanks to its solid financial performance an

6. • Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales

     Zacks· 2 days ago

     Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.

7. • 

     Regeneron misses earnings, revenue expectations By Investing.com

     Investing.com· 2 days ago

     Regeneron (NASDAQ:REGN) experienced a slight decline in its stock price, falling 1.82% after...

8. • 

     Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar

     InvestorPlace· 21 hours ago

     Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes...

9. • Regeneron records mixed results for Q1 as Eylea revenues fall

     Crain's New York Business· 1 day ago

     The slight dip was driven by decreases in sales of one eye disease drug, Eylea. While Schott predicted that the macular degeneration therapy would bring in $2.2 billion in sales, the medication ...

10. • 

      Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

      Zacks via Yahoo Finance· 4 days ago

      An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided ...